Pertuzumab: evolving therapeutic strategies in the management of HER2-overexpressing breast cancer

By O'Sullivan Ciara C   Swain Sandra M  

Expert Opinion on Biological Therapy, Vol. 13, Iss. 5, 2013-05 ,pp. : 779-790

Informa Healthcare

Access to resources Recommend Favorite

Triterpenes as Potential Dimerization Inhibitors of HIV-1 Protease

By Quere L.   Wenger T.   Schramm H.J.  

Biochemical and Biophysical Research Communications, Vol. 227, Iss. 2, 1996-10 ,pp. : 484-488

Elsevier

Access to resources Recommend Favorite

Reverse-phase protein microarray highlights HER2 signaling activation in immunohistochemistry/FISH/HER2-negative breast cancers

By Tessitore Alessandra   Zazzeroni Francesca   Alesse Edoardo  

Expert Review of Proteomics, Vol. 10, Iss. 3, 2013-06 ,pp. : 223-226

Informa Healthcare

Access to resources Recommend Favorite

Pertuzumab for the treatment of ovarian cancer

By Langdon Simon P   Faratian Dana   Nagumo Yoko   Mullen Peter   Harrison David J  

Expert Opinion on Biological Therapy, Vol. 10, Iss. 7, 2010-07 ,pp. : 1113-1120

Informa Healthcare

Access to resources Recommend Favorite

Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression

By Whiteside Theresa L  

Expert Opinion on Biological Therapy, Vol. 10, Iss. 7, 2010-07 ,pp. : 1019-1035

Informa Healthcare

Access to resources Recommend Favorite